303794-33-4

Basic information

• Product Name: 3-[2-(4-bromophenoxy)acetylamino]benzoic acid methyl ester
• Synonyms: 3-[2-(4-bromophenoxy)acetylamino]benzoic acid methyl ester
• CAS NO: 303794-33-4
• Molecular Weight: 364.195
• Mol File: 303794-33-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-[2-(4-bromophenoxy)acetylamino]benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(4-bromophenoxy)acetylamino]benzoic acid methyl ester(303794-33-4)
• EPA Substance Registry System: 3-[2-(4-bromophenoxy)acetylamino]benzoic acid methyl ester(303794-33-4)

Safety Data

• Hazardous Substances Data: 303794-33-4(Hazardous Substances Data)

Upstream product

• 106-41-2 4-bromo-phenol 
• 6964-29-0 ethyl 2-(4-bromophenoxy)acetate 
• 4518-10-9 Methyl 3-aminobenzoate 
• 1878-91-7 (4-bromophenoxy)acetic acid 

Downstream Products

• 934594-03-3 3-[2-(3'-nitrobiphenyl-4-yloxy)acetylamino]benzoic acid methyl ester 
• 303032-14-6 3-[2-(4'-methylbiphenyl-4-yloxy)acetylamino]benzoic acid methyl ester 
• 934594-04-4 3-[2-(3'-methoxybiphenyl-4-yloxy)acetylamino]benzoic acid methyl ester 
• 1360869-92-6 3-[2-(4'-tert-butylbiphenyl-4-yloxy)acetylamino]benzoic acid 
• 1360869-74-4 3-[2-(4'-tert-butylbiphenyl-4-yloxy)acetylamino]benzoic acid methyl ester 
• 1418738-37-0 C₁₈H₂₅B₁₀NO₄ 
• 1427079-28-4 C₁₈H₁₅NO₄ 

Relevant articles and documents

Development of hypoxia-inducible factor (HIF)-1α inhibitors: Effect of ortho-carborane substituents on HIF transcriptional activity under hypoxia

A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI50) using the MTT assay. Among the compounds synthesized, 1g and 1l showed significant inhibition of hypoxia-induced HIF-1 transcriptional activity (IC50: 1.9 ± 0.4 and 1.4 ± 0.2 μM, respectively). Both compounds suppressed HIF-1α accumulation in a concentration-dependent manner. The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC50: 6.80 ± 0.25 μM) and this inhibition activity was higher than that of ETB (IC50: 10.9 ± 0.63 μM).

COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT

Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.

(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors

Structural modification of a compound discovered during screening using an HRE-dependent reporter assay has revealed a novel class of HIF-1 inhibitors, which potently inhibit the HIF-1α protein accumulation and its target gene expression under hypoxic conditions in human hepatocellular carcinoma Hep3B cells.